Payment overview · 2025
General Payments
$3,873.60
311 reported records · 35 companies
Healthcare provider profile · identity verified
Caryn M Vogel, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · INDIANAPOLIS, IN · NPI 1437157435
Verified facts
What the public records show
CMS Open Payments records show Caryn M Vogel, MD received $3,873.60 in general payments during 2025 across 311 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 10.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 48 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Briviact, Ingrezza, Nuplazid, Nurtec Odt, Qulipta, Ubrelvy, Vumerity.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Botox by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Ubrelvy by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Nuplazid by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rytary by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VUMERITY as an associated drug or biological on 16193 records involving 4044 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vumerity by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REYVOW as an associated drug or biological on 378 records involving 290 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Reyvow by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Ingrezza by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Nurtec Odt by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Austedo by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Briviact by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $392.54 | 10.1% | 34 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $390.99 | 10.1% | 39 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $361.94 | 9.3% | 29 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $230.45 | 6.0% | 22 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$226.12 | 5.8% | 23 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $205.29 | 5.3% | 15 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $186.64 | 4.8% | 24 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $183.42 | 4.7% | 9 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $153.07 | 4.0% | 6 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $151.29 | 3.9% | 6 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$146.29 | 3.8% | 15 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $146.12 | 3.8% | 18 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $139.04 | 3.6% | 9 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $137.03 | 3.5% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $130.31 | 3.4% | 16 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $94.77 | 2.5% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $85.10 | 2.2% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $68.23 | 1.8% | 3 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $57.72 | 1.5% | 3 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $54.41 | 1.4% | 3 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $42.58 | 1.1% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $33.12 | 0.9% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $31.18 | 0.8% | 2 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $28.11 | 0.7% | 1 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $25.51 | 0.7% | 1 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $22.02 | 0.6% | 1 | 2025 |
| SpringWorks Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.86 | 0.6% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $20.68 | 0.5% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.27 | 0.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.93 | 0.5% | 1 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $15.92 | 0.4% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $14.14 | 0.4% | 1 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $14.08 | 0.4% | 1 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $13.82 | 0.4% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $13.61 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,658.62 | 308 |
| Education | $214.98 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $314.71 | 26 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $310.79 | 25 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $261.90 | 27 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $226.12 | 23 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $209.35 | 20 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $206.85 | 29 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $186.64 | 24 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $183.42 | 9 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $153.07 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $152.75 | 19 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $146.12 | 18 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $139.04 | 9 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $139.04 | 9 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $137.03 | 11 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $116.09 | 8 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $105.81 | 13 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $101.70 | 10 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $96.30 | 5 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $85.10 | 4 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $68.23 | 3 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $54.41 | 3 | 2025 |
Source payment records
|
|||||
| Zilbrysq Normalized: zilbrysq |
Drug | UCB, Inc. | $52.94 | 3 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $47.23 | 3 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $42.58 | 2 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $38.29 | 2 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $36.26 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $33.12 | 2 | 2025 |
Source payment records
|
|||||
| AVONEX Normalized: avonex |
Biological | Biogen, Inc. | $31.67 | 2 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $31.18 | 2 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | Octapharma USA, Inc. | $28.11 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $27.39 | 2 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $25.70 | 3 | 2025 |
Source payment records
|
|||||
| Bafiertam Normalized: bafiertam |
Drug | Cycle Pharmaceuticals Inc | $25.51 | 1 | 2025 |
Source payment records
|
|||||
| EMGALITY Normalized: emgality |
Drug | Lilly USA, LLC | $24.50 | 3 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $22.02 | 1 | 2025 |
Source payment records
|
|||||
| OGSIVEO Normalized: ogsiveo |
Drug | SpringWorks Therapeutics, Inc. | $21.86 | 1 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $21.10 | 2 | 2025 |
Source payment records
|
|||||
| Ocrevus Normalized: ocrevus |
Biological | Genentech USA, Inc. | $20.75 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $20.68 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $18.27 | 1 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $17.93 | 1 | 2025 |
Source payment records
|
|||||
| AMPYRA Normalized: ampyra |
Drug | Merz Pharmaceuticals, LLC | $15.92 | 1 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $15.92 | 1 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $14.14 | 1 | 2025 |
Source payment records
|
|||||
| FYCOMPA Normalized: fycompa |
Drug | CATALYST PHARMACEUTICALS, INC. | $14.08 | 1 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $13.82 | 1 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $13.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Briviact briviact |
2025 | Briviact | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 70 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 45 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VUMERITY vumerity |
2025 | Vumerity | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
45 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | VUMERITY open payments reported associated product |
CMS Open Payments — General Payments 16193 supporting records · 4044 recipient NPIs · example record 1208299697 |
Vumerity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | REYVOW open payments reported associated product |
CMS Open Payments — General Payments 378 supporting records · 290 recipient NPIs · example record 1186470979 |
Reyvow · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
70 | 11 |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 399 | 106 |
| Duloxetine Hcl | Duloxetine Hcl | 210 | 51 |
| Levetiracetam | Levetiracetam | 193 | 49 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 169 | 48 |
| Pregabalin | Pregabalin | 167 | 39 |
| Memantine Hcl | Memantine Hcl | 165 | 53 |
| Sumatriptan Succinate | Sumatriptan Succinate | 163 | 39 |
| Primidone | Primidone | 149 | 44 |
| Amitriptyline Hcl | Amitriptyline Hcl | 134 | 36 |
| Topiramate | Topiramate | 111 | 33 |
| Donepezil Hcl | Donepezil Hcl | 109 | 36 |
| Lamotrigine | Lamotrigine | 95 | 24 |
| Emgality Pen | Galcanezumab-Gnlm | 89 | 14 |
| Clonazepam | Clonazepam | 77 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 77 | 21 |
| Aimovig Autoinjector | Erenumab-Aooe | 70 | 13 |
| Nurtec Odt | Rimegepant Sulfate | 70 | 11 |
| Baclofen | Baclofen | 68 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 67 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 66 | 19 |
| Diazepam | Diazepam | 65 | 11 |
| Alprazolam | Alprazolam | 59 | 12 |
| Carbamazepine | Carbamazepine | 58 | 12 |
| Zonisamide | Zonisamide | 58 | 11 |
| Propranolol Hcl Er | Propranolol Hcl | 56 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 53 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | 12 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 49 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 46 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 46 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 46 | 17 |
| Trazodone Hcl | Trazodone Hcl | 46 | 17 |
| Qulipta | Atogepant | 45 | 11 |
| Oxcarbazepine | Oxcarbazepine | 44 | 14 |
| Propranolol Hcl | Propranolol Hcl | 44 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 43 | 16 |
| Amantadine | Amantadine Hcl | 40 | 14 |
| Divalproex Sodium | Divalproex Sodium | 40 | suppressed |
| Phenytoin | Phenytoin | 40 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 36 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 35 | 11 |
| Tramadol Hcl | Tramadol Hcl | 34 | suppressed |
| Carbamazepine Er | Carbamazepine | 32 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 32 | 11 |
| Methylphenidate Hcl | Methylphenidate Hcl | 32 | suppressed |
| Ondansetron Odt | Ondansetron | 31 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 30 | suppressed |
| Lorazepam | Lorazepam | 30 | suppressed |
| Meloxicam | Meloxicam | 30 | suppressed |
| Armodafinil | Armodafinil | 29 | suppressed |
| Modafinil | Modafinil | 28 | 11 |
| Divalproex Sodium Er | Divalproex Sodium | 25 | 11 |
| Levetiracetam Er | Levetiracetam | 25 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 23 | suppressed |
| Carisoprodol | Carisoprodol | 23 | suppressed |
| Glatiramer Acetate | Glatiramer Acetate | 23 | suppressed |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 22 | suppressed |
| Nourianz | Istradefylline | 22 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 22 | suppressed |
| Acetazolamide | Acetazolamide | 21 | suppressed |
| Ingrezza | Valbenazine Tosylate | 21 | suppressed |
| Lacosamide | Lacosamide | 21 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Gocovri | Amantadine Hcl | 18 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 17 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Reyvow | Lasmiditan Succinate | 17 | suppressed |
| Ubrelvy | Ubrogepant | 17 | suppressed |
| Botox | Onabotulinumtoxina | 16 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 16 | suppressed |
| Briviact | Brivaracetam | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 15 | suppressed |
| Prednisone | Prednisone | 14 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Austedo | Deutetrabenazine | 12 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 12 | suppressed |
| Rytary | Carbidopa/Levodopa | 12 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 12 | suppressed |
| Lamotrigine Er | Lamotrigine | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Vumerity | Diroximel Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,873.60 · 311 records | Teva Pharmaceuticals USA, Inc. | AJOVY, AMPYRA, AUSTEDO XR, AVONEX, Auvelity, BRIUMVI, Bafiertam, Briviact, CREXONT, DAYBUE, EMGALITY, FYCOMPA, HYQVIA, Hizentra, INBRIJA, INGREZZA, JOURNAVX, KESIMPTA, KISUNLA, LUMRYZ, Leqembi, NUPLAZID, NURTEC ODT, OGSIVEO, Ocrevus, Ocrevus Zunovo, PANZYGA, PONVORY, QULIPTA, REXULTI, Rystiggo, Sunosi, Symbravo, TYSABRI, UBRELVY, ULTOMIRIS, UPLIZNA, VALTOCO, VUMERITY, VYALEV, VYEPTI, VYVGART, VYVGART HYTRULO, WAINUA, WAKIX, XYWAV, ZAVZPRET, Zilbrysq | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Briviact play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error